Youguo Long

Key Laboratory Of Regenerative Biology South China Institute For Stem Cell Biology And Regenerative Medicine
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36.

FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36.

Journal: Science translational medicine

Published: August 26, 2026

Integrin β6-Targeted CAR-T Cells exhibit potent antitumor activity in β6-Positive pancreatic ductal adenocarcinoma and lung adenocarcinoma.

Integrin β6-Targeted CAR-T Cells exhibit potent antitumor activity in β6-Positive pancreatic ductal adenocarcinoma and lung adenocarcinoma.

Journal: Molecular cancer therapeutics

Published: October 17, 2025

DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity.

DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity.

Journal: Science immunology

Published: March 21, 2025

RELA Ablation Contributes to Progression of Hepatocellular Carcinoma with TP53R249S Mutation and is a Potential Therapeutic Target.

RELA Ablation Contributes to Progression of Hepatocellular Carcinoma with TP53R249S Mutation and is a Potential Therapeutic Target.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: January 07, 2025

Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.

Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.

Journal: Molecular therapy. Oncology

Published: September 15, 2023

The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.

The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.

Journal: International immunopharmacology

Published: March 07, 2023

CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer.

CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer.

Journal: Clinical and experimental medicine

Published: September 05, 2022

Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels.

Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels.

Journal: Molecular therapy oncolytics

Published: September 04, 2022

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D.

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D.

Journal: Molecular therapy oncolytics

Published: April 29, 2022

Human induced-T-to-natural killer cells have potent anti-tumour activities.

Human induced-T-to-natural killer cells have potent anti-tumour activities.

Journal: Biomarker research

Published: January 28, 2022

Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors.

Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors.

Journal: EMBO reports

Published: November 04, 2021

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies.

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies.

Journal: Frontiers in immunology

Published: November 03, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026